Nepafenac Shortage: What Providers and Prescribers Need to Know in 2026

Nepafenac (Nevanac 0.1%, Ilevro 0.3%) is a standard component of many post-cataract surgery NSAID regimens. If your patients have been reporting difficulty filling prescriptions, or if you've received callbacks from pharmacies about stock issues, here is a current briefing on Nepafenac's availability landscape in 2026 — along with practical guidance for managing access challenges.

Current Supply Chain Status

As of early 2026, Nepafenac is not listed on the FDA's official drug shortage database. The NDA transfer from Novartis/Alcon to Harrow Eye was completed in 2023, and distribution is now managed through Harrow's Cardinal Cordlogistics partner with McKesson and AmerisourceBergen as wholesale distributors — a well-established supply channel.

Despite stable national supply, localized availability challenges persist due to several factors specific to ophthalmic specialty medications:

• Demand clusters around surgical scheduling — pharmacies near ambulatory surgery centers experience periodic spikes
• No generic alternative currently available (as of January 2026), limiting supply redundancy
• High unit cost ($370–$480 retail) means some pharmacies stock minimally unless demand is confirmed
• Formulary variability — some major payers classify Nevanac and Ilevro differently, creating gaps in patient access depending on insurance plan

Formulary Considerations for Nevanac and Ilevro

Approximately 80% of commercial insurance plans cover Nevanac, with typical copays of $60–$80. Coverage for Ilevro (0.3%) is more variable. Some payers require step therapy — specifically, failure of a lower-cost ophthalmic NSAID (typically generic Ketorolac) before approving Nevanac or Ilevro. Prior authorization requirements are common for brand Nepafenac on formularies that include generic alternatives.

Medicare Part D coverage also varies by plan; some plans may classify Nepafenac as a specialty or non-preferred tier drug. It's worth checking your highest-volume payers' current formulary status for both Nevanac and Ilevro to anticipate patient access issues.

Clinical Alternatives to Nepafenac for Cataract Surgery

All four FDA-approved topical NSAIDs for cataract surgery have demonstrated efficacy for pain and inflammation management. Here is a clinical summary:

• Bromfenac 0.07% (Prolensa, generic): Once-daily dosing; starts day after surgery; generic available ($80–$200). Network meta-analysis showed superior visual acuity outcomes at 1 month vs. Nepafenac 0.1%.
• Ketorolac 0.4–0.5% (Acular, Acular LS, Acuvail, generic): QID dosing; widest availability; lowest cost ($15–$50 generic); preservative-free formulation (Acuvail 0.45%) available for patients with ocular surface disease.
• Diclofenac 0.1% (generic): QID dosing; affordable generic ($20–$60); long clinical track record.

Clinical Considerations When Switching from Nepafenac

When substituting an alternative NSAID, consider the following:

• Dosing protocol differences: Nepafenac (both formulations) starts the day BEFORE surgery. Bromfenac typically starts the day AFTER. If substituting within 24 hours of surgery, confirm your preferred pre-surgical NSAID protocol.
• High-risk patients: Patients with diabetes, prior uveitis, or history of CME are at elevated risk for post-surgical macular edema. For these patients, Nepafenac 0.3% (Ilevro) has EU-approved labeling for macular edema risk reduction in diabetics, which may inform your choice when substituting.
• Ocular surface considerations: For patients with severe dry eye or corneal disease, Acuvail (ketorolac 0.45% preservative-free) reduces the preservative burden, which may be preferable to other formulations.

Workflow Recommendations to Reduce Patient Access Problems

Several workflow changes can significantly reduce the number of patients who arrive on surgery day without their prescribed NSAID drops:

1. Send all post-op prescriptions at the pre-op visit (typically 1–2 weeks before surgery), not the day of. This gives patients time to fill them and resolve any access issues.
2. Include a preferred pharmacy recommendation in your pre-op materials — especially one you know stocks Nepafenac reliably.
3. Use medfinder for Providers to check pharmacy stock in real time before patients leave your office, and direct them to the closest pharmacy that has their prescription in stock.
4. Maintain a small office sample inventory of Nepafenac or an alternative NSAID to bridge patients who cannot fill before surgery day.
5. Pre-authorize high-complexity patients early in the surgical workup — especially those on plans likely to require PA for brand Nepafenac.

Patient Assistance Resources

For financially constrained patients:

• Harrow Patient Assistance Program: Eligible uninsured or underinsured patients may receive Nevanac or Ilevro at no charge. Eligibility typically requires income below $40,000 (individual) or $60,000 (couple).
• GoodRx / SingleCare coupons: Can reduce Nevanac cost from ~$413 to ~$321–$330 at participating pharmacies.
• Generic alternatives: Generic Ketorolac ($15–$50) and Diclofenac ophthalmic ($20–$60) are clinically effective and substantially more affordable for uninsured or high-copay patients.

Summary for Providers

Nepafenac is not in an official shortage in 2026, but localized pharmacy availability gaps require proactive management. Sending prescriptions early, knowing your formulary landscape, maintaining sample coverage, and using tools like medfinder for Providers to identify stocking pharmacies can dramatically reduce day-of-surgery access failures. When Nepafenac is unavailable, generic Bromfenac, Ketorolac, and Diclofenac are all proven alternatives.